Biotech firm Caris Life Sciences has acquired Pharmatech, an oncology-focused site management organization (SMO) that has developed a way to speed up trial enrollment.
Pharmatech, an originator of the Just-In-Time rapid enrollment system, also brings to the table the largest research-ready oncology network, Caris said, a network it will utilize to connect hundreds of cancer research centers across the nation.
Caris’ acquisition is intended to shift the company from a traditional physician outreach model to a real-time approach that takes care of patient identification at the lab. The strategy removes the need for patients to travel to a central trial site by enabling the patient to be enrolled days earlier and stay in the local physician’s care.
“The acquisition promises to fundamentally redefine how pharmaceutical and biotechnology companies identify and rapidly enroll patients in precision oncology trials,” Caris said.